Oriola Oyj (ORIOLA.HE)
- Previous Close
1.0860 - Open
1.0880 - Bid 1.0860 x --
- Ask 1.0900 x --
- Day's Range
1.0700 - 1.0900 - 52 Week Range
0.9470 - 1.0980 - Volume
63,385 - Avg. Volume
125,843 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jul 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.15
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company also distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. Oriola Oyj was founded in 1907 and is headquartered in Espoo, Finland.
oriola.com864
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: ORIOLA.HE
View MorePerformance Overview: ORIOLA.HE
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORIOLA.HE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORIOLA.HE
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.20%
Return on Assets (ttm)
0.94%
Return on Equity (ttm)
-13.19%
Revenue (ttm)
1.68B
Net Income Avi to Common (ttm)
-20.1M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
113.5M
Total Debt/Equity (mrq)
57.42%
Levered Free Cash Flow (ttm)
38.31M